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ABSTRACT
With the recent launch of the Global Development Lab in the Hunter and Stephanie Hunt Institute for Engineering and Humanity,
fellows, faculty, and industry professionals have been working to create meaningful solutions to promote a resilient humanity,
addressing the UN’s Sustainable Development Goals and challenges. The Institute has taken on Dr. Ali Beskok’s project, the
development of a low cost, portable, Point-of-Care-Device for humanitarian and health applications. This paper provides a
systematic review of current Point-of-Care-Devices using antibody antigen reactions. Additionally, it provides aspects of a market
analysis and a literature review. Its overarching goal is to make recommendations regarding a disease the developing device could
test for through antibody antigen reactions that would most positively affect global health. Traditionally, biomedical engineers have
developed technologies in response to the needs of the developed world’s medical community. These approaches often do not
address the needs of the majority of the world’s peoples afflicted with both communicable and non-communicable diseases as the
developments are far too costly and those with most need have, at best, limited access to supporting clinical laboratory infrastructure
in developing countries. A gap in care has emerged as a result of these conditions. As a result, Drs. Beskok and Koklu have
developed a Lab-on-a-Chip technology that can test for a chosen disease with a turnaround time of just a few seconds and a detection
limit of 1 ng of antigen per 1 mL of sample fluid. In contrast to other commonly used PoCD’s, this technology can be adapted for
detection of various diseases in various settings. This is a great improvement to current devices on the market in specificity,
sensitivity, and ease of use, therefore making it particularly useful in high-throughput, low-skill staffing environments.18 In creating
disease selection criteria for Dr. Beskok and his team’s device, several factors were taken into consideration. Generally, the
selection criteria consists of diseases that result in a high DALY value, are communicable, identifiable with antibody-antigen
reactions, and can be tested for using urine. The diseases that were identified with this criterion were Tuberculosis and Malaria.
Various antibody-antigen recommendations for diagnosis, advantages, and limitations of the proposed Point-of-Care-Device are
discussed in the Proposed Disease section. In addition, current funding for each disease is overviewed. In order to make the greatest
impact, deployment of the PoCD in the Sub-Saharan region, most specifically the Democratic Republic of Congo and Sierra Leone
are recommended. Furthermore, children under the age of 5 who suffer from malnutrition should be given special attention.
Focusing in these locations and populations will best aid in accomplishing the third Sustainable Development Goal set out by the
UN: to ensure healthy lives and promote wellbeing for all at all ages.

1.

INTRODUCTION
Inequalities in health between population groups
exist in all countries and furthermore between countries.
Conversations regarding global health equity have recently
become more prominent as decentralized medical systems
and universal health coverage have become more commonly
practiced. Equity is defined by the World Health
Organization as “the absence of avoidable, unfair, or
remediable differences among groups of people, whether
those groups are defined socially, economically,
demographically or geographically or by other means of
stratification.”1 When you apply this term to health care, it
implies that all people should have the opportunity to attain
their full health potential and that no one should be
disadvantaged from achieving this potential. This being said,
it is widely accepted that as various social determinants
affect heath determinants, variance in wealth, power, and
prestige create systematic differences. These differences can

be seen along socioeconomic, political, ethnic, cultural and
even gender lines. Often times, the causes of such
inequalities vary between developing countries and
developed countries. Additionally, access to medical care
often varies with different infrastructure, education, and
engineering practices.
Traditionally, biomedical engineers have worked
to develop technologies in response to the needs of the
world’s developed community. However, these devices are
often out of reach and inadequate to support the needs of the
majority of the world’s people who are afflicted with
infectious diseases. These groups often only have access to
poorly resourced health care facilities with little to no
supporting clinical laboratory infrastructure. A gap in care
has emerged as a result of these conditions. A major
challenge for the biomedical engineering community is to
develop diagnostic tests to meet the needs of these people,
the majority of whom are in the developing world. In order

1 In cooperation with The Hunt Institute for Engineering and Humanity.
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to address this challenge, our team of multidisciplinary
students and subject matter experts have been working to
improve the current immunoassay diagnostic standard
through Lab-on-a-Chip technology by developing a portable
Point-of-Care-Device.
The remainder of the paper will provide a
systematic review on current and emerging Point-of-CareDevices currently being used in countries with developing
and developed economies. Next, it provides an overview of
the diagnostic capabilities of the device being designed by
Dr. Ali Beskok and his team on the Southern Methodist
University campus. Selected diseases that have the biggest
global impact on DALY measures and are appropriate for
Point-of-Care diagnosis will be reviewed. Lastly, locations,
populations, and people who will benefit most are identified.

1.1.
Mission Statements
1.1.1 The Hunt Institute for Engineering and
Humanity
Our mission is to serve as a national and
international hub to partner with leaders in business,
academia, NGOs, and government, in order to develop and
scale sustainable and affordable technologies and solutions
to the challenges facing people locally and globally. Our hub
connects students, industry professionals, community
members, faculty, and staff. Our innovation is evidenced
through faculty-lead student research and demonstration
projects that are focused on solving issues that impact
humanity.

1.1.2

The Global Development Lab

The goal of the Hunt Institute Global
Development Lab (GDL) is to foster innovative solutions for
a resilient humanity addressing the UN's Sustainable
Development Goals. The GDL selects innovative ideas with
potential for transformational impact and provides
programmatic support, in-kind and financial, to help develop
them from the idea to proof of concept stage.

1.2

Sustainable Development Goals

In 1945, the United Nations (UN), an
intergovernmental organization responsible for maintaining
international peace and security, developing friendly
relations among nations, achieving international
cooperation, and harmonizing the actions of nations, was
formed with the ratification of the United Nations Charter.
In doing so, various nations signaled their commitment to
battle issues confronting humanity in the 21st century, such
as peace and security, climate change, sustainable
development, human rights, disarmament, terrorism,
humanitarian and health emergencies, gender equality,
governance, food production, and more.2
In 2000, 191 UN member states met to develop 8
goals concerning direct improvements in well-being, all of
which were set to be achieved by 2015. Known as the
Millennium Development Goals (MDGs), these goals set to
(1) eradicate extreme poverty and hunger; (2) achieve
universal primary education; (3) promote gender equality
and empower women; (4) reduce child mortality; (5)
improve maternal health; (6) combat HIV/AIDS, malaria,
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and other diseases; (7) ensure environmental sustainability;
and (8) develop a global partnership for development.2
By 2015, the end of the MDG period, the world
had seen remarkable gains in the anti-poverty movement.
With much more work to be done, a bold new agenda was
developed to transform the world to better meet the human
needs and the requirements of economic transformation,
while protecting the environment, ensuring peace, and
realizing human rights.1 On January 1st, 2016, the 17
Sustainable Development Goals of the 2030 Agenda for
Sustainable Development were created. With 169 targets,
these 17 goals aim to address—in a manner that works for
all people—the root causes of poverty and the universal need
for development. Broadly, these goals are: (1) to end poverty
in all its forms everywhere; (2) to end hunger, achieve food
security and improved nutrition, and promote sustainable
agriculture; (3) to ensure healthy lives and promote wellbeing for all at all ages; (4) to ensure inclusive and quality
education for all and promote lifelong learning; (5) to
achieve gender equality and empower women and girls; (6)
to ensure access to water and sanitation for all; (7) to ensure
access to affordable, reliable, sustainable, and modern
energy for all; (8) to promote inclusive and sustainable
economic growth, employment, and decent work for all; (9)
to build resilient infrastructure, promote sustainable
industrialization, and foster innovation; (10) to reduce
inequality within and among countries; (11) to make cities
inclusive, safe, resilient, and sustainable; (12) to ensure
sustainable consumption and production patterns; (13) to
take urgent action to combat climate change and its impacts;
(14) to conserve and sustainably use the oceans, seas, and
marine resources; (15) to sustainably manage forests,
combat deforestation, halt and reverse land degradation, and
halt biodiversity loss; (16) to promote just, peaceful, and
inclusive societies; (17) and to revitalize the global
partnership for sustainable development.

1.3
SDG 3: Ensure Healthy Lives and
Promote Wellbeing for All at All Ages
The Third Sustainable Development Goal aims to
ensure healthy lives by promoting the well-being of those at
all ages.3 Broken down into nine subsections, this ambitious
goal looks to both address structural issues within the health
care sector while also finding new cures to better address
high mortality rates. Although significant strides have been
made in this sector, there are still great distances to go in
order in order to accomplish the newly identified targets by
2030. Primarily due to the interconnected relationship of
health care and macroeconomic performance, progress
towards meeting this goal has been uneven both between and
within countries.1 Although many important milestones have
been reached, national averages hide the fact that many are
still being left behind. Ensuring healthy lives and well-being
for all at all ages is also contingent upon completing other
goals set out by the United Nations such as water and
sanitation, gender equality, climate change, and peace and
stability. In order to accomplish these goals, the United
Nations works in conglomeration with entities in the private
and public sectors such as non-governmental agencies, nonprofits, and government entities. Together, these bodies
work to make positive impacts on the lives of humans around
the world.
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Countries are often put into the three categories of
developed economies, economies in transition, and
developing economies.1 As technology and means of
transportation have advanced, maintaining and supporting
the articles laid out in the Universal Declaration of Human
Rights become more complex and stratified than ever. These
articles dictate human rights that are claimed to be
unalienable for all in all places, but reality does not always
align with these claims. Many of the Sustainable
Development Goals directly relate to attaining these rights.
For example, relating to Goal 3, Article 25 states: “(1)
Everyone has the right to a standard of living adequate for
the health and well-being of himself and of his family,
including food, clothing, housing and medical care and
necessary social services, and the right to security in the
event of unemployment, sickness, disability, widowhood,
old age or other lack of livelihood in circumstances beyond
his control” and, “(2) motherhood and childhood are entitled
to special care and assistance.”3 Although there have been
many debates and conversations regarding the broad
wording of these statements, the world still sees grave
inequalities in access to and the distribution of health care.
Many of these disparities exist between majority and
minority, rich and poor, and urban and rural populations. In
addition to this, across the world, children are at a higher risk
of dying than the poor.3 That being said, nearly all child
deaths occur in countries with developing economies. The
average under 5 mortality rate for those living in developed
countries was 5 deaths per 1,000 live births.1 For those living
in low income countries, the average under 5 mortality rate
was 68 deaths per 1,000 live births.1 In order to accomplish
the SDG’s set out by the UN, efforts must be focused on the
locations and populations with the highest need. Common
terminology in sustainable development refers to this
concept as creating the “greatest impact.” Regionally, of the
countries with the 20 highest child mortality rates, the vast
majority are located in Africa with the exceptions being
Haiti ranked at number 7 and Afghanistan ranked at number
11.1

2.
2.1
2.1.1

DIAGNOSTIC PRACTICES
Technical Aspects
Antibody-Antigen Reactions

When pathogens enter the body, they can trigger
humoral immunity. This occurs when an antigen, a foreign
substance that elicits an immune response, binds to its
specific immunoglobulin (Ig) receptor on B cells. These B
cells are then stimulated to proliferate and produce
antibodies. Antibodies are Ig proteins that either directly kill
their specific antigen or flag it for destruction. Antibodies
can be monoclonal, meaning one antibody binds to only one
antigen, or polyclonal, meaning one antibody can recognize
and bind to multiple antigens. In either instance, the binding
between antibodies and antigens is extremely specific.4

2.1.2

Immunoassays

Immunoassays utilize the reactions between
antibodies and antigens to detect and quantify the presence
of a pathogen. Immunoassays are highly beneficial because
of their inherent extreme specificity and sensitivity. The
most common immunoassays include radioimmunoassay,
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chemiluminescenceimmunoassay, counting immunoassay,
enzyme
linked
immunosorbent
assay,
and
fluoroimmunoassay.4
ELISA, or enzyme linked immunosorbent assay,
is the most common immunoassay that utilizes competitive,
direct, indirect, or sandwich assay methods, as well as
enzyme conjugated antibodies to produce a quantified
result.5 ELISA tests have a high throughput and are highly
specific and sensitive.4 But ELISA, and many other
conventional immunoassays, are limited by their high cost,
lack of portability, slow analysis time, utilization of
additional sophisticated instruments, and requirement of a
skilled user.6 Therefore, currently used immunoassay
techniques are not necessarily suitable for diagnosing
diseases in developing communities.

2.1.3

Point of Care Technologies

Lab-on-a-Chip, or LoC, devices aim to be “chip
sized” recreations of an entire biological laboratory. Because
of their small size, LoC’s are portable, simple to use, low
cost, low in energy consumption, require only small biofluid
sample sizes, and rapidly produce results.7 LoC technologies
align with the ASSURED guidelines of Point-of-CareTesting and are therefore better diagnostic options for less
developed areas.
Point-of-Care-Testing (PoCT) or Point-of-CareDevices (PoCD) are those that can provide diagnostic results
while the user is nearby or with the patient. This diagnostic
method should be rapid, low-cost, and simple. Point-ofCare-Testing can be separated into two categories: small,
handheld devices, such as Lab-on-a-Chip technologies, or
desktop instruments that are simplified versions of preexisting technologies.8 Many PoCDs use immunoassays to
detect the presence of pathogenic substances and are
recommended for use in low-resource areas as long as they
follow the ASSURED guidelines. These ASSURED
guidelines are set by the World Health Organization and are
discussed in Section 2.3.2.
The Point-of-Care-Device developed by Drs.
Beskok and Koklu utilizes Lab-on-a-Chip technology and
contains nanorods coated with an antibody which has a
specific and strong affinity for a particular antigen. When a
biofluid sample is run through the device, only the antigen
of interest, or target molecule, will bind to the antibodies
covering the nanorods. The binding will then generate an
impedance value that can be read as a quantified value of
antigen present in the sample. Information on the PoCD is
continued in Section 3.0.

2.2
Developed Countries Current and
Developing Diagnostic Practices
Diagnostic technologies and trends tend to emerge
first in developed countries. Though some technologies
primarily in use in developed countries are reviewed in this
report, there are many diagnostic technologies that continue
to change the medical field but are not currently feasible to
implement outside of stable, resource-rich environments. To
better combat trends, such as overgeneralized treatment with
antibiotics – leading to increased rates of antibiotic-resistant
strains, the medical community is shifting the way they
provide treatment. Specifically, the medical community is
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putting an emphasis on developing faster, high-specificity,
high-sensitivity diagnostics to pin-point exact strains before
pharmaceutical treatment.
A majority of research and development (R&D)
takes place in developed countries because such locations
are both hubs for R&D funding and allow for sooner
availability to patients. However, developed countries often
have different diagnostic goals that are not always directly
applicable to the developing world. While a shift has begun
to occur in developing countries, the highest burdens of
diseases remain from communicable diseases.9 In contrast,
noncommunicable and chronic diseases elicit higher burdens
of disease in developed countries.

2.2.1 Current Diagnostic Practices in
Developed Countries
Centralized laboratories are facilities dedicated to
lab testing and assessment, localizing diagnostic services to
medical institutions as a whole. Laboratory tests which were
once outsourced to facilities miles away for processing now
have the ability to be done on site. The in-house capability
greatly reduces time from initial sample to diagnostic result
and therefore time to treatment. In addition, faster result
turnaround reduces the potential for a patient with a
communicable disease to expose non-infected persons. The
centralized laboratory has also allowed off-site labs to
become more specialized in their testing and reduce cost to
hospital per test. Typically, laboratory-based-testing has few
limitations, which are often outweighed by the benefits of
specificity, timeliness, and information provided. Because of
large size, high cost, and specific skillset required,
immunoassay systems such as ELISA and other diagnostic
instruments are commonly a part of these centralized
laboratory facilities.
In state-sponsored healthcare systems, such as that
of the U.K., there is a growing trend towards the laboratory
network. A laboratory network allows for smaller
laboratories to specialize in a specific set of medical tests,
distributing fixed-initial cost over the system for testing that
requires specialized equipment. This process allows for
reduced per-test-cost and reduces redundancies, but is only
viable where transportation challenges can be overcome and
transmission of results is efficient and reliable.
Digital Diagnostic medicine, as defined by the
Digital Therapeutics Alliance, seeks to “deliver evidencebased therapeutic interventions to patients that are driven by
high quality software programs to prevent, manage, or treat
a broad spectrum of physical, mental, and behavioral
conditions.”10 PricewaterhouseCoopers (PwC) outlines a
trend in developed countries towards Digital Diagnostic
medicine as well as digital vital sign tracking, which allow
for the implementation of personalized medicine. In
developed countries, greater levels of resources allow for
more expensive digital Point-of-Care-Devices that can
interface with smart watches, smart phones, and more. There
has been an observable shift in developed countries towards
decentralized medical care that focuses on keeping patients
out of hospital and treated by satellite health partners when
needs arise.11

Although there is still a need for highly skilled
workers to produce diagnostic data for patients, some of this
need is being lessened in developed countries. Patient and
market comfortability with telemedicine—allowing for
physicians to view data remotely, conference with patients
via mobile apps, and opt for attachments to smart phones that
enable Point-of-Care applications—is on the rise.10 In
developed countries, issues with internet connection, power
usage, and access to highly specialized labs are significantly
reduced, but some of the factors that allow for the rise of
highly specialized central care, decentralized general care,
and “smart” medicine are not as readily or consistently
available in the developing countries.10
Within current diagnostic markets, PoCT and
immunoassays hold strong market-share, at near 35% and
25% respectively, and continue to trend with higher than
average market growth (see Figure 1) 2. Although globally
beneficial, developed countries possess strong enough
infrastructure for significant R&D and deployment. POC
devices serve as a way to incorporate personalized medicine
and increase safety in infectious disease diagnostics for
patients in the U.S., U.K., and Europe.9

2.2.2 Emerging Diagnostic Practices of
Developed Countries
Within developed countries, there are several
immunoassay or near-patient devices of interest on the rise.
In particular, Curetis has launched a class of devices that can
act as a diagnostic near-patient tool for any number of
chronic and infectious diseases that commonly affect
developed countries. This class of devices all use a prepared
cartridge-style table-top system to diagnose strains of
Pneumonia; detect implant, tissue, intraabdominal, and
Urinary Tract infections; and perform blood culture. The
company has plans to continue increasing the range of
cartridges available.12
For example, Unyvero is a Curetis device that can
perform the processes described above. One study compared
the abilities of Unyvero and the PLY-ELISA immunoassay
to diagnose Pneumonia.13 The PLY-ELISA immunoassay is
a well-accepted method for pneumonia strain-specific
detection, but it takes substantially longer to process than
Unyvero. With an increasing global need for better
diagnostics in order to combat antibiotic-resistance,
technology like the Unyvero device not only fills this gap,
but does so in a near-to-patient, quick, simple way. In
independent studies testing the efficacy of Unyvero’s
pneumonia specific cartridge, it performed as well as
traditional PLY-ELISA in sensitivity, although not
specificity (see Figure 2). However, it is important to note
the particular strain tested is not common in developed
countries, and therefore Unyvero is still considered a very
viable option. In more common strains, Unyvero performed
consistently near or above 90% in specificity.12, 13

2 All figures appear in Appendix 3, starting on page 15.
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2.3
Developing Countries: Current and
Developing Diagnostic Practices
Diagnostic technologies are equally as important
for health care within the developing world. Proper
diagnostic methods are critical to accurately and effectively
treat patients and ultimately save lives. Current issues such
as antibiotic resistance, cost of care, and communicable
disease pandemics have all ignited a growing interest in
investing in diagnostic technology across the globe.11 With
that being said, many of the tools currently used to diagnose
disease in low-resource settings are not suitable for the
communities they are meant to serve. Many of the diagnostic
practices used in developing countries are modeled off
practices used in developed countries. Developed countries
are focused on tackling noncommunicable health problems,
and despite a rise in these ailments within the developing
world, infectious disease remains most prevalent within
many developing countries.14 As a result, the massprocessing automated machines and lab tests that are
common within the developed world are often too
expensive, resource-dependent, and time consuming for
developing areas.

2.3.1 Current Diagnostic Practices in
Developing Countries
While a centralized laboratory is often considered
the gold standard within developed countries, the standard
and quantity of these labs are often lower in developing
countries. The centralized lab allows for complex tests,
incredibly specific and sensitive diagnoses, and advanced
technologies. Often, lack of support for qualified personnel,
limited funding, geographic barriers, and quantity of
centralized labs and instruments result in various limitations.
These include but are not limited to: a high ratio of samples
to laboratories and qualified personnel, lack of proper
resources and supplies, sample transportation time, and
lengthy result turnaround.14 Inconsistent and sparse access
to electricity and water are another reason that hospital
laboratories are insufficient within developing countries. In
conclusion, “gold standard” laboratories are rare in the
developing world and current labs do not produce similar
results.
In an effort to mitigate the problems presented by
centralized labs, the number of rural clinics has increased.
With hopes of being lower-cost and more geographically
accessible, local clinics are similar to the developed world’s
physician’s office.14, 15 These clinics run quick diagnostic
tests, often utilizing the less expensive and simpler lateral
flow methods of diagnosis.16 But, these tests have poor
sensitivity, around 31.3%, and rural clinics still do not
possess the staff and resources necessary to be a complete
solution.16
The most common way that a diagnosis is reached
in developing countries is through symptomatic review.14 In
this case, treatment is given to patients dependent on the
prevalence of a certain disease within a community and how
well patient symptoms align with that disease. While
diagnosing diseases in this way can be cost- and resourceeffective, there are also downfalls. For example, deciding to
treat for Malaria in Sub-Saharan Africa by review of
symptoms is up to 88% specific but only up to 66%
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sensitive.17 This means that only up to 66% of reviewed
patients are correctly diagnosed as not having Malaria.
Patients can be incorrectly treated for diseases that they do
not have, while their true ailments go untreated.
In summary, the most common diagnostic issues
within developing areas include staffing constraints, lack of
quality lab and medical resources, lack of reliable water and
electricity, geographic access to health care, and cost.
Diagnostic practices currently being used within less
developed countries are often based off of the methods of the
developed world. This misalignment of diagnostic practices
creates a need for the development of new diagnostic
technologies.

2.3.2 Emerging Diagnostic Practices in
Developing Countries
Point-of-Care diagnostic technologies seek to fill
the gap created by current diagnostic practices, especially
within developing countries. The WHO has outlined the
ideal diagnostic technology for less developed communities.
This technology should be ASSURED—affordable,
sensitive, specific, user-friendly, rapid, equipment-free, and
deliverable to patients.18
A POC test should be cost-effective for both
providers and patients. Determining cost-effectiveness
should include measurements of the price of the test, disease
prevalence, cost of treatment, cost of mistreatment, and
throughput. In areas where POC technology is most needed,
health care providers and their patients often lack abundant
budgets, funding, and resources. Therefore, new
technologies must be cost-effective.
The device should also be sensitive and specific.
The test should produce few false positives and few false
negatives if it is going to achieve what other diagnostic
methods do not. Ideally, the technology should also be
multiplex, or capable of detecting multiple different
antigens, in order to best come to a conclusive diagnosis. To
mediate the misdiagnosis, and therefore mistreatment, of
disease in underdeveloped countries, a PoCD must be both
sensitive and specific.
Due to the limitations posed by the small number
of skilled, qualified health care workers, a PoCD needs to be
simple. The device should be simple enough that those
without medical training should be able to perform the test.
In addition, the biofluidic sample used should be easy to
obtain and handle. Diagnostic results should be presented in
a way that is easy to understand and record.
In addition, the developed diagnostic technology
should be rapid in order to best prevent mistreatment,
correctly treat patients, and also optimize efficacy of that
treatment. The PoCD should output within a small enough
time period that treatment can begin during that same visit—
hence, “point of care.”
A PoCD needs to be portable to truly live up to its
name. This means that the device should be small, robust,
and easy to move around. The device should not require
large equipment or machinery to operate. These qualities
ensure the portability of the device as well as successful
operation without the need for extraneous supplies or
resources.
Finally, POC technology needs to be deliverable
to those who need it most. Whether in rural clinics or
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emergency response settings, patients in need must be
physically able to access diagnosis.

3.
3.1

PROPOSED DEVICE
Current Device

The technology developed by Dr. Ali Beskok and
Dr. Anil Koklu in Southern Methodist University’s (SMU)
Biomicrofluidics Lab utilizes Lab-on-a-Chip technology
that aims to be a possible solution for diagnosis of disease,
especially for implementation in developing communities.
The appropriate development of this technology has been
informed by the ASSURED criteria suggested by the
WHO.14 An overview is provided in the paragraphs below
but for further technical explanations of the methodology
and capabilities of the device, please refer to the article
published in Analytical Chemistry titled: Rapid and
Sensitive Detection of Nanomolecules by an AC
Electrothermal
Flow
Facilitated
Impedance
Immunosensor.18 To see a configuration of the device refer
to Figure 3.
This technology fundamentally functions
similarly to other LoC devices, it utilizes antibody-antigen
reactions to detect the presence of pathogens. Conventional
immunosensors are often limited by low sensitivity and long
detection times as they typically rely on passive diffusion.
Uniquely, this LoC utilizes a pumping loop and the system
can analyze both high and low conductivity physiological
fluids such as urine, saliva, and blood. As the sample fluid is
pumped through channels, it interacts with nanorod
electrodes coated with a certain antibody. The pumping loop
utilizes the micro stirring effect of AC electrothermal flow
and structural advantage of nanorod-covered interdigitated
electrodes with impedance spectroscopy to analyze a
physiological fluid.18 The nanostructured electrodes of the
LoC increase the surface area for binding interactions to
occur, which widens the frequency range for impedance
measurements. In addition, the hydrophilic surface of the
LoC reduces nonspecific binding and lowers friction to
improve pumping. These techniques allow for analytes to
bind onto nanorod surfaces within a few seconds and
enriches the number of binding molecules. The nanorods can
be also be programmed, or coated in new antibodies, in order
to attract different antigens, depending on which disease the
user would like to test for. This allows the LoC to be flexible
for target molecules detected, while the combination of the
chip’s surface and nanostructuring dramatically increase the
sensitivity.18 If the biofluidic sample contains the specific
antigen that binds the selected antibody configured to the
device, the antibody-antigen reaction will increase
impedance within the circuit. The increased impedance
value is then measured and used to quantify the amount of
antigen within the sample.
In summary, Drs. Beskok and Koklu have
developed a novel Lab-on-a-Chip technology that can test
for a chosen disease with a turnaround time of just a few
seconds and a detection limit of 1 ng of antigen per 1 mL of
sample fluid. In contrast to other commonly used PoCD’s,
this technology can be adapted for detection of various
diseases in various settings. This is a great improvement to
current devices on the market in specificity, sensitivity, and
ease of use, making it particularly useful in high-throughput,
low-skill staffing environments.18
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3.1.1

Limitations of Current Device

The current technology still faces a few limiting
factors. As of now, the Lab-on-a-Chip requires two
additional pieces of equipment: a function generator and an
impedance analyzer (see Figure 3). The function generator
is necessary for signal production, which is needed for the
chip’s functionality, and the impedance analyzer is needed
to produce impedance values. These pieces of equipment are
large and high-cost. Therefore, the current technology fails
to be small, portable, and inexpensive. The current LoC
technology is also only capable of testing for one antigen
using one antibody, which means that diagnosis is not
multiplex. Biosafety level restrictions and limited funds for
further lab instruments have hindered further development
of the device. Without an increase in the Lab’s biosafety
level, usage of pathogens and higher-level biofluids needed
for device testing and development are unavailable. With
further
partnerships
and
grant-approval,
further
developments will be made. These goals are elaborated on
in Section 3.2.

3.2

Goal Device

Although the current device is still in
development, further benefits are expected with continued
development. Although the current device already has high
detection specificity and flexibility in target diseases,
increased funding will lead to development of elliptical
pumps that will allow for an increase in multiplex detection
to 10 species.
Due to the antibody fixing method and single-use
design of the chip, there is flexibility to fit various desired
applications. Such increased flexibility allows for location
specific and population specific diagnosis criteria. Further
development also aims to allow for nanorods to be coated in
multiple antigens, allowing for multiplex assays. Because of
the impedance based detection design of multiple species as
well as the single use structure of the LoC, it is expected that
there will be little to no cross-contamination .
In addition, the goal LoC utilizes a cyclical
pumping loop. By using a cyclically pumped loop system,
with no external pump components, the device is able to
reduce the amount of patient specimen needed for detection,
past the 1ng/mL mentioned earlier, increasing sensitivity.
The nanostructured surfaces within the detection
zone increase the binding surface area and allow wider
frequency range for impedance measurements.
The hybrid surfaces further reduce nonspecific
binding on the walls of the device and enable low friction to
pump the fluid.
In terms of buffers and fluids used for the device,
the microfluid transport is suitable for both low and high
conductivity. For global usage, the breadth allowed in
buffers increases the possible supplier market and allows for
greater in-field flexibility while prepping samples.
The device can be developed as a handheld device
or the Lab-on-a-Chip (LoC) can be incorporated with an
external app through an impedance measurement interface.
The final device will include components that allow
impedance detection and function generation without
traditional lab devices, such as the AFG1062 Tektronix
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Arbitrary Waveform Generator – retail for $1,240 – or the
Agilent / HP 4294A Precision Impedance Analyzer, 40 Hz
to 110 MHz – retailing for $37,495.

3.2.1

Limitations of Goal Device

Though there are numerous discussed benefits, the
device also presents limitations—even in an ideal condition.
Before the chip is used, the glass plates must be
cautiously transported to avoid breaking the glass. These
glass plates provide both the top and bottom portion of the
current chip, with nanorods and more being sandwiched inbetween. These nanostructures, situated between the glass
plates, are vital that for greater surface area in detection. The
technology to safely transport glass plates is widely on the
market; however, transportation limitations must be noted as
a possible concern.
The device also has limitations because of the need
for a secondary display. The complete device needs to
interface with a data output display for timely diagnostics,
and currently, this is a fixed cost that may or may not incur
variable cost of maintenance.
In addition, the secondary display which reads
impedance and generates the signal required for the
operation need to be portable. Furthermore, the device still
needs power infrastructure to be usable. Once again, these
extra parts are included in the fixed set-up cost incurred by
organizations to operate the portable device, and will present
a variable cost to the operation due to the need for future
replacement or maintenance.

4.

PROPOSED DISEASES
The World Health Organization defines health as
a state of complete physical, mental and social well-being
and not merely the absence of disease or infirmity. Human
rights doctrines that call for adequate health are also often
phrased broadly, making “good” hard to quantify. In
attempts to best describe and measure health phenomena on
a global scale, various health indicators have been developed
and standardized. In general, they are categorized into
proximal and distal indicators. Proximal indicators aim to
provide direct measurements by looking at diseases, deaths,
and use of services. Distal indicators aim to measure social
development, education, and poverty indicators.3
Medical practices and forms of treatment often
vary depending on access to resources. Quality of care is
generally comprised by the three sections of structure,
process, and outcomes. Structure refers to the material
characteristics such as infrastructure, tools, and technology.
Process refers to the interaction between caregivers and
patients during which structural inputs from the health care
system are transformed into health outcomes. Lastly,
outcomes can be measured in terms of health status, deaths,
or disability-adjusted life years—a measure that
encompasses the morbidity and mortality of patients or
groups of patients.19
Primarily through the practice of Epidemiology,
which looks at the incidence, distribution, and possible
control of diseases across the world, medical professionals
developed mathematical techniques to measure the rates of
death and disease. Certain measures quantify the risk of
occurrence of contraction and mortality where other rates
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more broadly measure years of life that are spent in good or
poor health. These measures help direct needs for policy
reforms, action plans and the provision of services. The most
comprehensive methods that do so are known as Disability
Adjusted Life Years (DALY).19 One DALY equates to one
lost year of healthy life. When DALY’s are added together
across a population, we can see a measurement of the gap
between the current health status and an ideal health
situation where the entire population lives to an advanced
age free of disease and disability. Quantifying the burden of
disease assists doctors, nurses, public health workers, and
other medical professionals as they work to measure the
performance of health on a global, regional, national, and
subnational scale. Because the highest DALY numbers
result from diseases that result in the disability of children,
these diseases are often prioritized on the global health
scale.19
In creating disease selection criteria for Dr.
Beskok and his team’s device, several factors were taken
into consideration. Generally, the selection criteria consists
of diseases that result in a high DALY value, are
communicable, identifiable with antibody-antigen reactions,
and can be tested for using urine. Because the LoC
microfluidic platforms are employed for POC diagnosis
purposes, they have low cost, low power consumption, short
analysis time, and use minute amounts of sample volumes.
Therefore, they are useful in higher stress or emergency
situations. Diseases with high rates of communicability are
those which spread and replicate rapidly. Early detection in
such cases allows for earlier treatment and decreased
infection rates. Accurate detection also decreases the rate of
misdiagnosis, maltreatment, and the possibility for the
development of antibiotic resistant strains. The diseases that
were identified with this criterion were Tuberculosis and
Malaria. Together, these diseases accounted for 89,011,364
years of healthy life lost in 2016.19

4.1

Tuberculosis

A WHO re port on global and regional
Tuberculosis (TB) incidents in Africa and South-East Asia
indicates that such incidents are nearly 70% of all incidents
world-wide. Annually, more than 95% of cases and deaths
from TB occur within developing countries. Those
undernourished are 3 times as likely to contract TB. In
addition, 1.1 million children (0–14 years of age) fell ill with
TB, and 230,000 children (including children with HIV
associated TB) died from the disease in 2018.20 These
numbers are striking, and the DALY values for TB rank in
the top 10 globally (see Figure 4).19
The treatment options for groups affected by TB
make it a great option for initial deployment of a rapiddiagnosis PoCD. TB continues to have a significant effect on
countries with developing economies and countries in
transition, and based on 2018 published numbers, is off track
for the UN Sustainability Goal 3, under which a target is to
end the epidemics of AIDS, TB, malaria and neglected
tropical diseases, and to combat hepatitis, water-borne
diseases and other communicable diseases.3
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Based on a report by the Treatment Action Group
(TAG) published in December 2018, global funding for TB
has remained steady since 2009, when adjusted for
inflation.21 These findings prove optimistic for the continued
interest in TB research and the Global End TB campaign.
When funding for TB is broken down into 5 major
categories, over the 2016 and 2017 funding periods, research
in vaccines and diagnostics still has a wide gap left for the 5year period. As funding organizations choose sector-specific
funding targets in the coming years, diagnostics are high on
the list with nearly $3.3 billion USD left to fund to meet the
5-year global funding target (see Figure 5). This monetarily
signifies a need for continued development and deployment
in the three areas of diagnostics, drugs, and vaccines.
The largest funder of TB world-wide has remained
the National Institute of Health (NIH) and the National
Institute of Allergy and Infectious Diseases (NIAID) under
the NIH. With continued bipartisan support for the NIH and
increased allocation over the years, support by the NIH to
TB funding is not expected to drop.22 In total, the United
States remains the top funder of TB research globally at $312
million, followed by the Bill and Melinda Gates
Foundation—the top philanthropic giver—at $126 million,
and in third place the European Union, at $37 million. It is
important to note, as a U.S. research initiative, the two top
funding resources globally reside in the U.S. In 2017, 66%
of funding has come from the public sector, with the private
sector coming in at 11%.22
The TAG report also makes mention of the
investment group, Unitaid.21 Unitaid is focused on investing
in innovations to prevent, diagnose and treat HIV/AIDS,
tuberculosis and malaria more quickly, affordably and
effectively.”23
Within funding for diagnostics, the best areas to
seek grant opportunities are from either public/government
funding, the Bill and Melinda Gates foundation, or Unitaid.
The U.S. remains a global leader in TB funding support and
research.

granuloma, containing the bacteria. While the granuloma
prevents the infection from spreading, the tissue within the
containment becomes necrotic and develops into a harmful
Gohn Complex.25 If the infection is contained by the
granuloma, it is latent and can later become activated. If
Tuberculosis becomes active soon after infection, it is
classified as Primary Tuberculosis.26
If the bacteria within the granulated tissue
survives, it can successfully spread throughout the lungs and
rest of the body, most commonly if the individual is
immunocompromised or the granuloma fails to contain the
bacterium.24, 25 Those at highest risk of developing Active
Tuberculosis from the latent form are children under five,
those infected with HIV, and those in communities with
increased incidence, especially medically underserved, low
income areas.26 Tuberculosis can cause further necrosis and
even cavity formation within the lungs and can lead to
complications in the pleura, larynx, bones, kidneys, lymph
nodes, and the brain.24 Active cases of Tuberculosis and its
further systemic complications are fatal if not detected and
treated properly.25
It is important to test for Tuberculosis as early as
possible to prevent progression from latent to active versions
and to provide accurate and efficient treatment in already
active cases. Rapid and early detection of the disease is
necessary to prevent these adverse outcomes. Individuals
with latent Tuberculosis are not contagious and cannot
spread the infection to others. But, because M. tuberculosis
is slow-growing and persistent, it can easily develop drug
resistance or later, further progress throughout the body.
Therefore, it is still necessary to quickly detect even latent
TB infections. Those with active TB are highly contagious
and can be for up to weeks after starting treatment.25 Due to
the differences in latent, primary, and active Tuberculosis,
there is no set critical period for the disease. Despite the
complexities posed by various stages of TB, early diagnosis
of the disease is one of the most effective ways to decrease
its negative impact on those diagnosed and their surround
communities.

4.1.2

4.1.3

4.1.1

Global Funding for Tuberculosis

Pathology of Tuberculosis

Tuberculosis is an infectious disease caused
mainly by the aerobic, rod-shaped bacteria M. tuberculosis.
Additional microbes, M. bovis and M. africanum, can also
induce Tuberculosis, but often only in underdeveloped areas.
M. tuberculosis is especially virulent because it is carried in
airborne droplet nuclei and can remain in the environment
for hours after a host has infected the space. The disease is
transmitted to an uninfected host by inhalation of a droplet
nuclei. Successful transmission of tuberculosis is impacted
by the susceptibility of the exposed person, the level of
exposure that an uninfected person experiences, the
infectiousness of the pathogen, and any environmental
factors that may increase or decrease virulence.24
If inhaled, M. tuberculosis can reach the alveoli of
the lungs. There the bacteria are recognized by macrophage
cells and targeted for destruction by lysosomes. M.
tuberculosis can then release proteins that inhibit the
hydrolytic functions of the lysosomes. While most
bacterium may be expelled or destroyed before being able to
cause an infection, often some successfully remain in the
lungs. The body’s immune response creates a covering, or

https://scholar.smu.edu/jour/vol6/iss1/2
DOI: https://doi.org/10.25172/jour.6.1.2

Diagnostic Methods for Tuberculosis

The gold standard for diagnosing Tuberculosis is
mycobacterial culturing using liquid media as this is the only
test that is considered to actually confirm the diagnosis of
Tuberculosis.27 TB cultures most commonly utilize sputum
as a biofluid sample, but other biofluids can also be used.
Cultures can differentiate between active and latent forms of
TB and can also determine if the sampled bacteria are drug
resistant. Mycobacterial cultures are highly specific and
sensitive and can diagnose TB with as little as 10-100 colony
forming units per mL of sample.28 While TB cultures are
considered to be the “gold standard” of TB testing, they are
not actually the most commonly used test. This is because
culturing a sample of bacteria requires extensive lab
equipment and biosafety clearance, has a turnaround time of
10 to 14 days, and is costly.27 Therefore, other methods are
often relied on to detect an individual’s exposure to TB.
TB is typically tested for using a purified protein
derivative (PPD) skin test. In this test, a purified protein of
the Tuberculosis bacteria, tuberculin, is injected
intradermally on the forearm.28 If the individual has been
previously exposed to M. tuberculosis, they will produce a
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localized reaction at the site of injection. This reaction is
then read by qualified personnel between 48 to 72 hours
post-injection and is then measured in millimeters of the
induration.28 The Tuberculosis skin test is inexpensive and
requires little to no sophisticated medical instruments or
laboratory equipment, making it one of the most common
forms of diagnosis. Despite this, there are limitations. The
test requires skilled personnel to read the results and patients
must be able and willing to return two to three days after
initial injection of tuberculin. In addition, a 2011 WHO
article stated that Tuberculosis skin tests have a pooled
sensitivity of 83% and specificity of 58%.29 Skin tests
conducted on those who are vaccinated for TB often result
in a false-positive.29 Lastly, this diagnostic method also only
informs if a patient has been exposed to TB and additional
testing is required to determine if the TB infection is actually
active.30

4.1.4 Recommendations for Dr. Beskok’s
Device
While cell-mediated immunity is much better
understood in the body’s response to TB, there is evidence
that humoral immunity plays a role in protection from the
disease.30 Lipoarabinomannan, or LAM, is a
lipopolysaccharide associated with the cell wall of M.
tuberculosis and is specifically bound by certain antibodies.
LAM can be detected in urine and is better for detecting TB
in those co-infected with HIV. For those with HIV
infections, it can be difficult to produce sputum, the biofluid
used in gold standard TB testing, and difficult to detect the
presence of an antigen due to low CD4+ cell counts.31
Because 11% of HIV patients also have TB and those with
HIV are at a 16-27 times greater risk to develop TB, it is
important to prioritize diagnostic methods that can detect for
tuberculosis in individuals that also have HIV.31 This is why
the LAM antigen is most highly recommended.
The only current commercialized rapid test for
detecting LAM is the Alere LF-LAM test. This is a Point-ofCare lateral flow test that detects the presence of LAM in
urine with 42% sensitivity and 91% specificity in
symptomatic patients.32 The Alere LF-LAM test has a limit
of detection (LOD) of 100 cells/μl, which is the
recommendation for PoCT made by the World Health
Organization.33 Because of the current test’s low sensitivity,
specific reagents with specific binding sites on LAM have
been studied to improve assay results. One study showed that
pairing capture antibody S4-20 with the A194-01 detection
antibody increased sensitivity to 93%, specificity to 97%,
and showed no cross-reactivity with other bacteria.34 This
pair of antibodies also detects Tuberculosis in those that are
HIV-negative with a high sensitivity of 80%. Therefore, it is
highly recommended that LAM antigen is detected using S420 and A194-01 antibodies.34
Not only can LAM be detected in urine, but
utilizing this biofluid as a sample for PoCD testing presents
other benefits. Urine based testing has advantages over
sputum, blood, and other biofluids as it is easy to collect,
handle, and store, and it lacks infection control risks that are
often associated with the collection of other biofluids.35
Urine enables a PoCD to be used by people with little to no
medical training as blood will not have to be drawn, nor
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sputum collected. Furthermore, utilizing urine allows for a
decrease in various anthropological cultural sensitivities.

4.1.4.1 Advantages and Limitations of Dr.
Beskok’s Device
In order to reach the Third SDG and End TB
Strategy set for 2030, further research and the development
of vaccines and/or biomedical devices is needed. The
advantages of a Point-of-Care-Device that can test for TB
would allow for a decreased time to diagnosis and therefore
faster access to treatments. This would not only decrease the
mortality rate but also decrease the rate of transmission from
person to person. Currently, there are no single rapid,
accurate and robust TB diagnostic test that recommended by
the WHO for use at the Point-of-Care.35
The most commonly used test, the Tuberculosis
skin test, requires the patient to return between 48 and 72
hours after the test is initiated. Dr. Beskok’s proposed device
would ideally allow for the patient to receive their results
within minutes.
Recent studies have also shown that differences in
antibody glycosylation can distinguish between active and
latent forms of TB. Specifically, the digalactosylated (G2)
Ab glycoform was found to be the best biomarker between
Active TB and Latent TB.36 With further research and
implementation of this glycoform, in addition to LAM
capturing, a PoCD could potentially detect TB in HIV
positive or negative patients, vaccinated patients, and also
differentiate between active and latent forms.
Alternatively, there are various limitations to take
into consideration. The development of a new PoCD is likely
to initially yield results that are less specific, less sensitive,
and have a higher LOD than current diagnostic methods such
as culturing and immunoassays. Currently, the device closest
to producing the desired results is the Alere-LAM diagnostic
test, costing only $3.50 per test.33 In order to surpass current
diagnostic methods, the proposed device must be more
sensitive and specific, cheaper, or faster than those already
on the market. In addition, further research needs to be
conducted on the specific antibody antigen reactions
recommended above for a TB PoCD.

4.2

Malaria

Malaria is currently a global epidemic. Within the
Africa region, the WHO reported Malaria as the 4th highest
DALYs percentage in 2016. At the start of the 20th century
Malaria was also ranked 4th on the DALY measure in the
African region. While the DALYs percentage has fallen
from 9.0 in 2000 to 5.8 in 2016, significant progress in
diagnostics and treatment still must be made in order to reach
the subset of the third SDG: to end Malaria by 2030.
Although Malaria persists an issue world-wide, the greatest
WHO region affected continues to be Africa with a
concentration in the Sub-Saharan region (see Figure 6).19
Other regions in need include Oceania and the
subcontinent of India (see Figure 7). Malaria is primarily
regionally transmittable and is a disease which will not affect
most developed countries due to geography. The affected
region conversation is important when talking about current
research, current funding, and incentives to the End Malaria
2030 goal.37
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The WHO notes “in sub-Saharan Africa, rapiddiagnostic tests (RDTs) are increasingly becoming the most
used method to test for malaria diagnosis among suspected
malaria patients in public health facilities. In 2017, an
estimated 75% of malaria tests were conducted using rapiddiagnostic tests, up from 40% in 2010.”38 These findings
help us to understand the readiness by the market for a POC
diagnostic solution for Malaria. Currently however, most
RDTs are only testing for one strain of Malaria—P.
falciparum— leaving a big need gap in the diagnostic market
for other strains tested.38

4.2.1

Global Funding for Malaria

Current funding efforts are concentrated within
Sub-Saharan Africa, with consistent funding from 2010 to
2017. However, global funding still has yet to meet funding
markers outlined by the SDG3. Three current areas of
greatest need for Malaria funding support fall to Africa, a
majority of South-East Asia, and areas of the Eastern
Mediterranean. Four big players in the Malaria Funding
sphere are Global Fund, PMI/USAID, World Bank and the
UK (see Figure 8).3
As noted in the Tuberculosis funding section,
Unitaid, an investment group focused on investing in
innovations to prevent, diagnose and treat HIV/AIDS,
tuberculosis, and malaria more quickly, affordably, and
effectively is also a great source of private funding for
Malaria diagnostic development and deployment.23
It is important to also realize that the Eastern
Mediterranean, though not prominently seen on the CDC
map of transmission, continues to be a high incidence area
for Malaria (see Figure 8). The countries included in Figure
8’s summary are: Afghanistan, Djibouti, Iran, Pakistan,
Saudi Arabia, Somalia, Sudan, and Yemen.
Within funding for Malaria diagnostics, the best
areas to seek grant opportunities are from public/government
funding or Global Fund, PMI/USAID, World Bank, the UK,
or Unitaid. The U.S. also remains a global leader in Malaria
funding support and research.23

4.2.2

Pathology of Malaria

Malaria is caused by four different protozoa that
are introduced by Anopheles mosquitoes. These four
protozoans are of the genus Plasmodium and include P.
falciparum, P. malariae, P. ovale, and P. vivax. It is
important to note that only Plasmodium falciparum causes
fatal disease. When feeding, female Anopheles inject
sporozoites into a human host. The immature sporozoites
then travel through the bloodstream and infect the liver,
where they mature and reproduce. After maturation in the
liver, cells rupture and release merozoites that invade red
blood cells. During the erythrocytic phase, the merozoites
reproduce by digesting hemoglobin and producing
hemozoin. This is called a schizont, which can then rupture
and release merozoites that will again undergo the
erythrocytic phase. Some merozoites then enter the
gametogony phase where the produced gametocytes can be
ingested by an Anopheles mosquito and new, infectious
sporozoites are formed that are passed along to a different
human host.39
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Most forms of malaria present with cyclic and
unspecific symptoms such as fever, headaches, and nausea.
Specifically, P. vivax and P. ovale can remain dormant in the
liver and cause later relapses of Malaria symptoms.40 This is
termed uncomplicated malaria and is considered a more mild
presentation of the disease, as it very rarely is fatal. Severe
malaria is caused only by P. falciparum and can lead to
organ failure and various complications including comas and
even death.38 Patients should be tested within seven days of
their first possible exposure to P. falciparum to three months
after their last possible exposure.40 Although P. falciparum
is inherently the most fatal form of Plasmodium species, lack
of access to proper medical resources and treatment make
the rapid diagnosis of any form of malaria imperative.39 With
simple and fast diagnosis through PoCD’s, patients in
underdeveloped communities are provided the opportunity
to early and proper treatment of disease.

4.2.3

Diagnostic Methods for Malaria

The gold standard for diagnosing malaria is
microscopic laboratory examination.41 Microscopy is
performed using both thick and thin smears of blood samples
under light microscopes to determine the presence of
Plasmodium parasites. Thick smears are used to confirm the
presence of parasites and thin smears are used to determine
parasite species.42 Microscopy has a limit of detection of 50500 parasites/μl of blood. Microscopy can be a fairly
quick—if proper resources are readily available—and
inexpensive way of diagnosing Malaria.43 With that being
said, microscopy can have very low sensitivity when
performed by unqualified personnel, is heavily-resource
dependent, is often limited by quality control, and can be
delayed in producing results when under certain
conditions.42 Low microscopy sensitivity can especially
result in a variance in diagnostic rates. This variance in
diagnosis can lead to excessive use of anti-malarial drugs or
negligent treatment, and therefore higher rates of morbidity
and the development of resistant strains of pathogens.
Therefore, rapid diagnostic tests are more commonly used in
low-resource areas.38
RDTs are often used and more readily available in
underdeveloped communities.38 RDTs utilize immunoassay
to detect the presence of varying Malaria pathogens. One
study compared the 13 best, according to the WHO-FIND
Product Testing Programme, Malaria rapid tests and found
that the best-performing test for detecting P. falciparum had
a LOD of 0.8 ng/mL. The best performing test for the other
three P. species was found to have an LOD of 25 ng/mL.
Overall, P. falciparum was better tested for than the other
three Plasmodium species.44 These RDTs present with the
same benefits as previously mentioned Point-of-Care-Tests,
such as low cost, simplicity, and portability. Despite the
numerous advantages, there are limitations to the current
rapid tests for Malaria. Current RDTs often only test for P.
falciparum or for the other three P. species and do not
possess very low limits of detection.44

4.2.4 Recommendations for Dr. Beskok’s
Device
Current immunoassays for detection of malaria
infection typically target histidine-rich protein 2 (HRP2) or
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Plasmodium lactate dehydrogenase (pLDH). HRP2 is
specific only to P. falciparum while pLDH is conserved
across all human malaria species.45 pLDH also has
Plasmodium species-specific epitopes, which allows for
discrimination between different Plasmodium species. PfpLDH is an epitope specific to P. falciparum, Pv-pLDH to
P. vivax, and Pvom-pLDH to P. vivax, P. ovale, and P.
Malariae. In addition, C-reactive protein (CRP), a human
inflammation marker, has been investigated as a biomarker
to differentiate viral from nonviral Malaria infections.44 One
study described the recent development of a multiplex
device capable of detecting HRP2, Pv-pLDH, Pvom-pLDH,
and CRP, with extremely low LODs (0.2 pg/ml, 9.3 pg/ml,
1.5 pg/ml, and 26.6 ng/ml, respectively) and without crossreactivity. While this study used blood as the biofluid
sample, as well as techniques that combined
chemiluminescence and ELISA, it does provide evidence for
the eventual development of a PoCD that can discriminate
between Malaria Plasmodium species, as well as viral versus
nonviral infections.45 In conclusion, it is recommended that
a PoCD be multiplex in its assay in order to increase test
sensitivity and specificity, as well as elicit the most effective
treatment plans for diagnosed persons, based on species
specific infection types.
Another recent rapid Malaria test of interest is the
Urine Malaria Test™, as it shows promise for diagnosing
Malaria with urine as the biofluid sample. This PoCT is a
simple dipstick test that detects the presence of P.
falciparum, through antibody specific binding to HRP2. This
urine test at a parasite density less than ≤ 200 parasites/μl
had a sensitivity of 50% and at density ≥ 201 parasites/μl
was 89.71% sensitive and 83.48% specific.46 So, while the
development and commercialization of a simple, rapid urine
PoCD for Malaria is encouraging, future PoCDs should
possess lower LODs, higher sensitivities, and higher
specificities.
It is also important to consider the specific WHO
recommendations for Malaria rapid diagnostic tests. The
WHO sets its standards for Malaria RDTs as having a limit
of detection of 200 parasites /μL, false positive rates less
than 10%, and invalid rates less than 5%.38

4.2.4.1 Advantages and Limitations of Dr.
Beskok’s Device
While numerous rapid tests have been produced
and implemented for use in the diagnosis of Malaria, there is
still a great need for continued development. Current
diagnostic methods are limited by low sensitivity, human
error, low limits of detection, detection of a singular
Plasmodium species, and biofluid sample used. Unlike
current RDTs for Malaria, Dr. Beskok’s device has a low
LOD compared to current commercial RDTs. Dr. Beskok’s
device also promises not to be just rapid, but also Point-ofCare, enabling fast result turnaround and appropriate use in
low-medical resource settings. In addition, further research
could potentially allow for a Point-of-Care-Test that is
multiplex and uses urine samples, rather than other biofluids.
The proposed device could possibly be limited by
cost-per-test as well as the already-high volume of rapid tests
for Malaria. RDTs and light microscopy both have estimated
costs of diagnosis that range from 1.0 to 2.0 US dollars,
making them extremely low-cost options.44 Also, the
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development of a multitude of Malaria RDTs, especially an
extremely sensitive multiplex test and a simple urine test,
possibly hinder the need for a new diagnostic device. With
that being said, the developed multiplex test uses blood,
which is more invasive and difficult to collect, handle and
store than urine, and is similar to the bulky, resourcedependent ELISA method. The Urine Malaria Test™ uses
an easier-to-handle biofluid and is extremely simple and
portable, but has poor limit of detection and sensitivity.

5.
5.1

GREATEST IMPACT
Location and People

Point-of-Care-Devices are designed to provide
care quickly and simply, lessening the need for sophisticated
laboratory equipment. Generating quick results offer health
professionals the ability to provide faster access to
appropriate treatments, therefore improving both clinical
and economic outcomes. Although the need for the
development of Point-of-Care-Devices exists globally,
factors which constitute POC technologies, such as their
ability to deliver less costly care and their transportability,
also allow for these devices to better address the heavy
burdens of diseases that disproportionately affect those in
remote locations. Throughout this report, measures which
quantify the need for new diagnostic technologies for TB
and Malaria were explored. In order to generate the highest
levels of impact, employing a PoCD in areas with high
incidence rates of these diseases are of most interest.
Tuberculosis is caused by an airborne pathogen
that thrives in densely populated environments, meaning it
is highly communicable. Key high-impact populations that
are at the greatest risk of initial TB infection are adults
during their most productive years and undernourished
children. Those at highest risk of progressing from Latent
TB to Active TB are children under five, those infected with
HIV, and those in communities with increased incidence.26
Malaria is a vector-borne disease, with climate
sensitive infected vectors (i.e., ticks and mosquitoes that
prefer warm temperatures with high humidity and high
rainfall).41 The most vulnerable group affected by malaria is
children under the age of five. Secondarily, pregnant women
are adversely affected.39
Globally, the region with the highest incidence
rates of these diseases is Sub-Saharan Africa, with TB
ranking at 237 per 100,000 people and Malaria ranking at
209.5 per 100,000 people.46,47 The country with the highest
incidence rate of Malaria is Rwanda with 505.6 cases per
every 100,000 people.48 The country with the highest
incidence rate of TB is Lesotho with 665 cases per every
100,000 people.47 The country that ranks highest for the
incidence rate of both TB and Malaria together is the
Democratic Republic of Congo. The country that ranks
second for the incidence rate of both TB and Malaria
together is Sierra Leone.47, 48
In 2014, the largest Ebola virus epidemic began in
Sierra Leone resulting in major loss of life and
socioeconomic disruption in the region. Furthermore, it
greatly reduced access to health services for diagnosis and
treatment for the major diseases that are endemic to the
region: malaria, HIV/AIDS, and tuberculosis. In 2018, the
10th outbreak of Ebola virus disease in the Democratic
Republic of Congo began, producing similar reductions in
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access to health services. Deterioration of health
infrastructure in these countries and fear of seeking care as a
result of these epidemics has exacerbated the already intense
need to rebuild health infrastructure and propose solutions to
decentralize care.49
In order to make the greatest impact, deployment
of the PoCD in the Sub-Saharan region, most specifically the
Democratic Republic of Congo and Sierra Leone are
recommended. Furthermore, children under the age of 5 who
suffer from malnutrition should be given special attention.
Focusing in these locations and populations will best aid in
accomplishing the Third Sustainable Development Goal set
out by the UN: to ensure healthy lives and promote
wellbeing for all at all ages.

6.
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Figure 1: Market share and expected growth of in vitro diagnostics. In vitro diagnostic tests are the broader umbrella of diagnostic
tests commonly used in the Global North. Immunoassay and POC devices fall within this market analysis.9
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Figure 2: Outlining sensitivity data collected from an analysis published in the Journal of Clinical Microbiology. The table directly
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Figure 3: Configuration of the experimental setup. A function generator supplied an AC potential to induce ACET flow to
concentrate target molecules onto the receptors-immobilized gold nanorod electrodes, and the binding was then measured using an
impedance analyzer for the quantification of the analyte.18
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Figure 1: 2016 DALY for Global, the African region, and the South-East Asia region as provided by the WHO’s report on leading
causes of death from 2000 to 2016.18

Figure 5: Graphic of compared funding from 2018 TAG report on 2005-2017 on Tuberculosis funding.21
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Figure 6: 2016 DALY for Global, the African region, and the South-East Asia region as provided by the WHO’s report on leading
causes of death from 2000 to 2016.18
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Figure 7: This map shows an approximation of the parts of the world where malaria transmission occurs, as supported by the CDC
report of global Malaria.37
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Figure 8: Contributions (USD) reported by donors for Malaria Funding in 3 main effected WHO geographical regions.23
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